Recent Updates — NVSEF

Novartis reported Q2 2026 net sales of USD 14.4 billion, a 3% increase (1% constant currencies), driven by priority brands Kisqali (+43% cc), Scemblix (+89% cc), and Leqvio (+59% cc). Core EPS for the quarter was USD 2.41. The company reaffirmed its full-year 2026 guidance, expecting low single-digit growth in net sales and a low single-digit decline in core operating income. Key strategic moves included the agreement to acquire Myricx Bio and the completed acquisitions of Pikavation Therapeutics and Excellergy. Net debt increased to USD 39.4 billion as of June 30, 2026, primarily due to M&A outflows of USD 15.3 billion and a USD 9.1 billion annual dividend payment. Novartis is an innovative medicines company operating in the pharmaceutical industry.